|
US6303121B1
(en)
*
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
KR20000034847A
(ko)
*
|
1998-11-17 |
2000-06-26 |
성재갑 |
인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
|
|
AU2002364935A1
(en)
|
2001-10-09 |
2003-06-23 |
Mayo Foundation For Medical Education And Research |
Enhancement of immune responses by 4-1bb-binding agents
|
|
US20030223989A1
(en)
|
2002-04-18 |
2003-12-04 |
Pluenneke John D. |
CD137 agonists to treat patients with IgE-mediated conditions
|
|
PL375144A1
(en)
*
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
US7288638B2
(en)
*
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
CN1997667A
(zh)
*
|
2004-05-10 |
2007-07-11 |
宏观基因有限公司 |
人源化FcγRⅡB特异性抗体及其使用方法
|
|
US20070253961A1
(en)
|
2004-06-09 |
2007-11-01 |
Ulsan Industrial Education Foundation |
Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis
|
|
US20060171929A1
(en)
*
|
2005-01-31 |
2006-08-03 |
The University Of Washington |
Regulation of dendritic cell functions by the DCAL-2 receptor
|
|
CA2609262A1
(en)
|
2005-06-03 |
2006-12-07 |
Mochida Pharmaceutical Co., Ltd. |
Anti-cd14 antibody fusion protein
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
WO2014055967A2
(en)
*
|
2012-10-05 |
2014-04-10 |
Neotope Biosciences Limited |
Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
|
|
CN104250302B
(zh)
*
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
|
AU2015264528A1
(en)
|
2014-05-21 |
2016-11-03 |
Kyowa Hakko Kirin Co., Ltd. |
Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
|
|
US20170247455A1
(en)
|
2014-08-22 |
2017-08-31 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
WO2017068183A1
(en)
|
2015-10-23 |
2017-04-27 |
Apogenix Ag |
Single-chain cd137-receptor agonist proteins
|
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技（上海）有限公司 |
抗pd-1抗体及其治疗用途
|
|
EP3464362B1
(en)
|
2016-05-27 |
2020-12-09 |
AbbVie Biotherapeutics Inc. |
Anti-4-1bb antibodies and their uses
|
|
BR112019005895A2
(pt)
*
|
2016-09-23 |
2019-06-11 |
Merus N.V. |
moléculas de ligação que modulam uma atividade biológica expressa por uma célula
|
|
MX395639B
(es)
*
|
2017-01-20 |
2025-03-25 |
Heidelberg Pharma Res Gmbh |
Composiciones y métodos para el agotamiento de células cd137+.
|
|
WO2018183520A1
(en)
*
|
2017-03-28 |
2018-10-04 |
Lyvgen Biopharma Holdings Limited |
Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
|
|
EP3634485A4
(en)
*
|
2017-06-07 |
2021-07-21 |
Silverback Therapeutics, Inc. |
CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES
|
|
WO2019109238A1
(en)
*
|
2017-12-05 |
2019-06-13 |
Lyvgen Biopharma Co., Ltd. |
Anti-cd137 antibodies and uses thereof
|
|
CN107982538B
(zh)
*
|
2017-12-26 |
2021-10-22 |
深圳市体内生物医药科技有限公司 |
一种药物组合物及其应用
|
|
WO2020069382A1
(en)
*
|
2018-09-28 |
2020-04-02 |
Lyvgen Biopharma Co., Ltd. |
Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof
|
|
TWI839395B
(zh)
*
|
2018-10-09 |
2024-04-21 |
瑞士商Ｎｕｍａｂ治療公司 |
靶向cd137的抗體及其使用方法
|